Immuron Pulls Plug On COVID-19 Treatment Hopeful, Citing Changing Landscape

Immuron Limited IMRN has deprioritized SARS-CoV-2 research to focus on the clinical development of more advanced-stage therapeutic drug candidates.
Immuron enters FY23 with a newly appointed CEO completing an assessment of the entire product portfolio, target markets, competitive advantage, and key growth drivers.
Related: Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19.
Considering research findings, the rapid evolution of the virus and changing treatment landscape present significant challenges to conducting a clinical trial for COVID-19 with IMM-124E.
Immuron has previously reported IMM-124E research investigations demonstrating neutralizing activity against COVID-19 infection.
Immuron has dedicated significant resources to interrogate the mechanism of SARS-CoV-2 protection. However, the mechanism of how IMM-124E protects against SARS-CoV-2 viral infection remains unclear.
Price Action: IMRN shares closed higher by 1.95% at $2.62 on Thursday.